

UNCOVERING CLEARANCE

Introducing SKYRIZI for adults with moderate to severe plaque psoriasis



PRESENTED BY

Andrew Blauvelt, MD, MBA

President, Oregon Medical Research Center

Andrew Blauvelt, MD, MBA, is President of the Oregon Medical Research Center in Portland, Oregon, where he also serves as Principal Investigator and owner. He is Professor of Dermatology at Oregon Health & Science University (OHSU) School of Medicine in Portland, and Adjunct Professor of Dermatology at the Uniformed Services University of the Health Sciences F. Edward Hebert School of Medicine in Bethesda, Maryland. Dr. Blauvelt earned his medical degree at OHSU School of Medicine, followed by his Master of Business Administration degree at OHSU and Portland State University.

DATE & TIME

Thursday, October 24, 2019

Registration: 6:00 PM

Presentation: 6:30 PM

LOCATION

Ringside Steakhouse

2165 W Burnside Street

Portland, Oregon 97210

PLEASE RSVP BY

October 18, 2019

John Carandanis (561) 866-5940

RSVP ONLINE

abbvie.meintl.com/DA202-BS07-19

Indication¹

SKYRIZI™ (risankizumab-rzaa) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Safety Considerations¹

SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on next page.

Please see accompanying full [Prescribing Information](#).

abbvie

©2019 AbbVie Inc. North Chicago, IL 60064
US-SKZ-190051 March 2019 DA202-BS07-19


Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection

Important Safety Information¹

Infection

SKYRIZI™ (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common ($\geq 1\%$) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie, Inc.

Please see accompanying full Prescribing Information.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals who practice in relevant specialties.

AbbVie tracks and reports payments and transfers of value to healthcare professionals under applicable state and federal reporting obligations.


Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection